RCE recce pharmaceuticals ltd

Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-13

  1. 4,176 Posts.
    lightbulb Created with Sketch. 501
    yes
    as we now on the cusp of entering phase 11
    i see this replicating the path of neu
    except with multiple times potential revenue prospects, as a result of much deeper need in patient population with added on wider applications across medical needs
    latest broker reports for neu anticipate fair value price target of around $10
    with similar amount of shares on issue i cant see why recce couldnt indeed exceed such value expectations
    given other similar precedents seen recently on little researched emerging biotechs a forecast valuation along those lines could clearly emerge
    neu with limited applications was priced around a dollar a year or so ago now what 5.78 with targets of $10
    recce seems a really good investment to me at this sub 1$ level with little downside
    if as expected now phase 1 tox human trials wrap up by end august and phase 11 schedules announced accordingly
    i think we will start to see a substantial gathering of interest and subsequent rerating
    have a peek at nsu
    just say later i told ya so !
    thanks for reading


 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
37.5¢
Change
0.000(0.00%)
Mkt cap ! $108.4M
Open High Low Value Volume
38.0¢ 39.0¢ 36.5¢ $39.00K 102.4K

Buyers (Bids)

No. Vol. Price($)
1 9999 37.5¢
 

Sellers (Offers)

Price($) Vol. No.
39.0¢ 2108 1
View Market Depth
Last trade - 16.10pm 08/08/2025 (20 minute delay) ?
RCE (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.